Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Polyvascular Disease [0.03%]
主动脉瓣狭窄患者合并多血管疾病经导管与外科主动脉瓣置換术的预后分析
Abdelrhman Abomoawad,Ramy Sedhom,Harsh Golwala et al.
Abdelrhman Abomoawad et al.
Introduction: There is a paucity of data regarding the trends and comparative outcomes of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) among patients with polyvascular dise...
An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records [0.03%]
利用电子健康记录进行的一项口服因子XIa抑制剂艾苏迪塞辛治疗房颤二期临床试验（PACIFIC-AF）的外部对照臂研究
Tatsiana Vaitsiakhovich,Alexander Hartenstein,Stephen Privitera et al.
Tatsiana Vaitsiakhovich et al.
Introduction: The aim of this study was to assess the applicability of an external control arm (ECA) approach in the clinical development of the oral factor XIa inhibitor asundexian for stroke prevention in patients with ...
Patient Experience of Heart Disease with Elevated Lipoprotein(a): Views from a Patient, His Physician, and a Patient Association [0.03%]
心血管病合并脂蛋白(a)升高的患者心声：来自患者、医生和患者的视角
Stéphane Favereaux,Vincent Durlach,Bernard Vercoustre
Stéphane Favereaux
This article presents three points of view on lipoprotein(a) [Lp(a)]: that of a patient, his endocrinologist, and a patient association, the Association Nationale des Hypercholestérolémies familiales et Lipoprotéines (a) (ANHET). By shar...
Left Ventricular Mechanical Circulatory Support Devices for Cardiogenic Shock After Myocardial Infarction [0.03%]
心肌梗死后发生心脏源性休克的左心室机械循环辅助装置
Duc M Giao,Robert P Giugliano
Duc M Giao
Cardiogenic shock is the most common cause of mortality in patients with acute myocardial infarction (AMI). Historically, AMI complicated by cardiogenic shock was associated with in-hospital survival of only ~50%. Recent advances in mechani...
Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia [0.03%]
阿托伐他汀/非诺贝特定剂量复方与阿托伐他汀单药对2型糖尿病合并脂代谢异常患者血脂谱的影响及安全性研究
Francisco G Padilla-Padilla,Lina N Ruiz-Bernes,Luis M Román-Pintos et al.
Francisco G Padilla-Padilla et al.
Introduction: In dyslipidemia associated with type 2 diabetes (T2DM), elevated triglycerides (TG), increased low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C) levels a...
Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study [0.03%]
巴西慢性冠状动脉综合征患者每天一次曲美他嗪80毫克的疗效和耐受性：V-GOOD观察研究
Luís Henrique Wolff Gowdak,Paulo Magno Martins Dourado,Dalton Bertolim Précoma et al.
Luís Henrique Wolff Gowdak et al.
Introduction: The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapi...
Arterial Hypertension and Associated Risk Factors in Kazakhstan: An Analysis of Blood Pressure Screening Results from May Measurement Month 2021-2023 [0.03%]
哈萨克斯坦高血压及相关危险因素分析：2021-2023年世界血压筛查月调查结果
Dilyara M Mukhtarkhanova,Gulnara A Junusbekova,Meiramgul K Tundybayeva et al.
Dilyara M Mukhtarkhanova et al.
Introduction: May Measurement Month (MMM) is a global campaign with the aim to improve awareness of arterial hypertension (AH). Kazakhstan participated in the campaign in 2021, 2022 and 2023. ...
Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study [0.03%]
mavacamten对梗阻性肥厚型心肌病患者超声心动图特征的影响：来自EXPLORER-CN研究的结果
Zhuang Tian,Xiaoyan Li,Liwen Li et al.
Zhuang Tian et al.
Introduction: Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with sympt...
Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide [0.03%]
优化血压控制的随机对照试验：厄贝沙坦氯噻酮与厄贝沙坦氢氯噻嗪的比较研究
Isabel E Rucker-Joerg,Ernesto G Cardona-Muñoz,Francisco G Padilla-Padilla et al.
Isabel E Rucker-Joerg et al.
Introduction: Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines suppor...
Defibrillation Threshold Testing After ICD Implantation in Patients with Chronic Kidney Disease [0.03%]
慢性肾病患者植入ICD后的除颤阈值测试
Rohit J Timal,Lano Osman,Joris I Rotmans et al.
Rohit J Timal et al.
Introduction: Routine defibrillation threshold (DFT) testing at the time of implantable cardioverter-defibrillator (ICD) implantation is no longer recommended because testing did not improve shock efficacy or reduce arrhy...